D. Western Therapeutics Institute, Inc. Reports Consolidated Financial Results for the Year Ended December 31, 2020
February 12, 2021
Share
D. Western Therapeutics Institute, Inc. reported Consolidated financial results for the year ended December 31, 2020. For the period, the company reported net sales of JPY 355 Million compared to JPY 580 Million a year ago. Operating loss was JPY 265 Million compared to Operating profit of JPY 117 Million a year ago. Loss attributable to owners of the parent was JPY 276 Million compared to profit attributable to owners of the parent of JPY 133 Million a year ago. Loss per share was JPY 10.16 compared to Earnings per share of JPY 5.07 a year ago. Loss was JPY 291,123,000 compared to profit of JPY 107,982,000 a year ago.
D.Western Therapeutics Institute, Inc. is a Japan-based company engaged in the research and development of new pharmaceuticals. The Company generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Companyâs drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The Company is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.
D. WESTERN THERAPEUTICS INSTITUTE, INC. 
